Athira Pharma (ATHA) Competitors $0.36 -0.02 (-5.78%) Closing price 04:00 PM EasternExtended Trading$0.36 -0.01 (-1.39%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHA vs. IZTC, CUE, HOWL, DRRX, ICCC, PDSB, DTIL, ATNM, INMB, and IMAShould you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Invizyne Technologies (IZTC), Cue Biopharma (CUE), Werewolf Therapeutics (HOWL), DURECT (DRRX), ImmuCell (ICCC), PDS Biotechnology (PDSB), Precision BioSciences (DTIL), Actinium Pharmaceuticals (ATNM), INmune Bio (INMB), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry. Athira Pharma vs. Its Competitors Invizyne Technologies Cue Biopharma Werewolf Therapeutics DURECT ImmuCell PDS Biotechnology Precision BioSciences Actinium Pharmaceuticals INmune Bio ImageneBio Invizyne Technologies (NASDAQ:IZTC) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends. Does the media favor IZTC or ATHA? In the previous week, Athira Pharma had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for Athira Pharma and 1 mentions for Invizyne Technologies. Athira Pharma's average media sentiment score of 0.96 beat Invizyne Technologies' score of 0.37 indicating that Athira Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Athira Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of IZTC or ATHA? 57.1% of Athira Pharma shares are owned by institutional investors. 22.1% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, IZTC or ATHA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/AAthira PharmaN/AN/A-$96.94M-$1.55-0.23 Is IZTC or ATHA more profitable? Invizyne Technologies' return on equity of 0.00% beat Athira Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Athira Pharma N/A -139.40%-106.84% Do analysts rate IZTC or ATHA? Athira Pharma has a consensus target price of $0.50, suggesting a potential upside of 38.89%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Athira Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAthira Pharma beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks. Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHA vs. The Competition Export to ExcelMetricAthira PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.07M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E RatioN/A21.3074.5925.92Price / SalesN/A240.30449.5483.33Price / CashN/A45.3337.0859.91Price / Book0.319.6112.156.29Net Income-$96.94M-$53.29M$3.28B$270.85M7 Day Performance-7.76%0.29%0.98%3.36%1 Month Performance-6.44%8.91%7.20%6.41%1 Year Performance-29.38%13.14%63.06%28.26% Athira Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHAAthira Pharma3.0858 of 5 stars$0.36-5.8%$0.50+38.9%-22.0%$15.07MN/A0.0040News CoverageGap DownHigh Trading VolumeIZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029News CoverageCUECue Biopharma2.7236 of 5 stars$0.78-2.7%N/A+29.9%$59.96M$9.29M-1.3960Positive NewsHOWLWerewolf Therapeutics3.9773 of 5 stars$1.31-5.8%$8.00+510.7%-36.2%$59.90M$1.88M-0.8040DRRXDURECT1.5187 of 5 stars$1.92-1.0%N/A+21.7%$59.62M$2.03M-19.2080News CoverageOptions VolumeICCCImmuCell1.3148 of 5 stars$6.40+4.6%N/A+61.7%$57.89M$26.49M33.6970Gap UpPDSBPDS Biotechnology2.3461 of 5 stars$1.24flat$10.00+706.5%-61.9%$57.83MN/A-1.3520Positive NewsDTILPrecision BioSciences4.1862 of 5 stars$4.90-2.4%$47.00+859.2%-52.4%$57.76M$68.70M-0.56200News CoverageGap DownATNMActinium Pharmaceuticals3.062 of 5 stars$1.78+2.3%$4.50+152.8%-13.8%$55.53MN/A-1.2830Positive NewsShort Interest ↑INMBINmune Bio2.9762 of 5 stars$2.03-2.9%$18.40+806.4%-68.4%$53.97M$10K-0.8210Positive NewsShort Interest ↓IMAImageneBio3.3512 of 5 stars$13.40-0.4%$35.50+164.9%-55.2%$53.87M$9.16M-1.7470Positive News Related Companies and Tools Related Companies IZTC Competitors CUE Competitors HOWL Competitors DRRX Competitors ICCC Competitors PDSB Competitors DTIL Competitors ATNM Competitors INMB Competitors IMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHA Stock Alerts